The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
AEDG
Epitalon is the compound in this book where the research history is longest, the provenance problem is most acute, and the gap between what the community believes and what the evidence actually shows is widest. Forty years of research is remarkable. The fact that nearly all of it comes from one scientist and one institution is the defining caveat.
The central tension resolved: Vladimir Khavinson discovered Epitalon, synthesized Epitalon, studied Epitalon, published on Epitalon, continues to publish on Epitalon, and leads the institution that holds commercial interest in Epitalon-related compounds. This is not a disqualification — every compound starts with a developer. But it is a limitation that compound science is designed to address through independent replication. Selank's Russian approval, reviewed in this book, came from two independent Russian institutions. Semax has Dolotov 2006 — an independent researcher confirming the BDNF finding. Epitalon's central claim — the one the entire longevity community is excited about — went 22 years without a meaningful independent attempt at replication. The Al-Dulaimi 2025 paper is a positive development. One paper from one independent group, 22 years later, confirming telomere elongation in cancer cell lines, is not the same as an established evidence base.
The strongest argument for Epitalon: it is the most mechanistically interesting longevity compound in this book from a pure biology perspective. Telomerase activation by a four-amino acid peptide, if the mechanism is real and generalizable, represents a genuinely elegant biological insight. The pineal/melatonin mechanism is well-supported and has a clear human application (sleep quality in aging). The animal data is consistent across species. The safety profile is genuinely clean. The compound has been studied for longer than any other in this book. And the 2025 wave of independent publications (Al-Dulaimi, Gatta, bovine oocyte) suggests the field is finally receiving the independent attention it has long deserved.
The strongest argument for caution: the evidence architecture is structurally fragile. One motivated researcher, one institution, 40 years of internally consistent data, one independent replication. The human 'clinical data' is non-randomized, single-institution, uses a different compound (Epithalamin), and was generated by the same people who developed and commercialize the compound. The most exciting claim — telomere elongation in living humans — has never been tested in a controlled trial. The PCAC review is for insomnia, not longevity, reflecting the FDA's appropriately conservative reading of what the evidence actually supports.
The pineal gland is a pea-sized structure at the center of the brain whose role in human biology has been debated for centuries. René Descartes called it the 'seat of the soul.' Modern neuroscience knows it as the primary producer of melatonin, the hormone that regulates circadian rhythms and sleep-wake cycles. By the 1970s, a growing body of evidence from Soviet research suggested that the pineal gland was also a master regulator of aging — that its functional decline with age contributed to the broader deterioration of neuroendocrine function, immunity, and longevity. This idea drove Vladimir Khavinson's research program for the next five decades.
Vladimir Khavinson is a professor of gerontology and director of the St. Petersburg Institute of Bioregulation and Gerontology, a Russian state scientific institution. Beginning in the 1970s and continuing through the 1980s, Khavinson developed a systematic program of extracting biologically active peptide fractions from various organs and tissues — including the pineal gland, thymus, brain cortex, retina, and multiple other organs — and studying their regulatory effects on cells and organisms. These extracts, called cytomaxes, were complex polypeptide mixtures derived from specific bovine tissues. The pineal gland cytomaxe was named Epithalamin.
Epithalamin is a polypeptide extract — not a single defined molecule, but a mixture of biologically active fractions from bovine pineal gland tissue. Khavinson's group treated elderly patients with Epithalamin in open-label clinical programs at their institute in St. Petersburg, and reported striking improvements: restored melatonin rhythms, improved immune function, and reduced mortality in long-term follow-up compared to historical controls. Epithalamin was registered as a medication in Russia. But as a complex biological extract, it was difficult to standardize, impossible to fully characterize, and challenging to study mechanistically.
The next step in Khavinson's program was identifying the active fraction of Epithalamin responsible for its biological effects. Through systematic fractionation and bioassay-guided analysis, his group identified a specific tetrapeptide — four amino acids: Alanine-Glutamic acid-Aspartic acid-Glycine — that appeared to capture Epithalamin's key regulatory activities in a defined, synthesizable form. They named it Epitalon. As a synthetic tetrapeptide with a known sequence, Epitalon could be manufactured reproducibly, studied mechanistically, and potentially developed as a pharmaceutical.
In 2003, Khavinson [1] et al. published what would become the compound's most-cited and most-discussed finding: Epitalon activated telomerase in human fetal lung fibroblasts that were previously telomerase-negative, and the treated cells exceeded the Hayflick limit — dividing more times than the 50-70 divisions that mark the end of normal somatic cell lifespan. This was a remarkable finding. A four-amino-acid synthetic peptide, activating telomerase in human cells. It positioned Epitalon directly in the center of what would become, in the subsequent decade, one of the hottest topics in aging biology: telomere length and telomere maintenance as biomarkers and potential targets of aging intervention.
The longevity community found Epitalon. By the 2010s and accelerating through the 2020s, Epitalon became a staple in biohacking and longevity protocols. It was presented — and marketed — as the compound with 'decades of human clinical evidence' and 'proven telomerase activation.' Both claims have a kernel of truth that requires careful qualification. The decades of research are real. The human clinical evidence is from Khavinson's own institute, from non-randomized studies, and much of it is from Epithalamin rather than pure Epitalon. The telomerase activation is real in cell culture. Whether SubQ injection of Epitalon elongates telomeres in living humans is a separate question that has never been addressed by a controlled clinical trial.
THE CENTRAL TENSION — THE FULL STATEMENT
Epitalon has more published research behind it than almost any other compound in the longevity peptide space — 40+ years, multiple species, multiple tissue types, telomerase activation, lifespan extension in animals, melatonin restoration in humans. It also has the most concentrated provenance of any compound in this book: essentially all of this research comes from one man and one institute, for whom the compound's success is directly tied to their scientific legacy and institutional mission. The first meaningful independent Western replication of the central telomerase claim appeared in 2025 — 22 years after Khavinson published it. That gap is not evidence the compound doesn't work. It is evidence that the evidence has not been stress-tested by adversarial independent replication in the way that science requires for high confidence. 40 years of internally consistent research from one source is not the same as 40 years of independent replicated science. Both descriptions of the evidence are technically accurate. Only one of them is scientifically precise.
Epitalon's evidence hierarchy differs from most compounds in this book. The most human-relevant finding (melatonin restoration) is the most evidence-supported but least discussed by the community. The most-discussed finding (telomere elongation) has the most concentrated provenance and weakest translation to in vivo human benefit. Both are documented accurately below.
Age-related decline in pineal melatonin production is well-established — melatonin output declines progressively from the third decade. The consequences include disrupted circadian rhythms, impaired sleep, reduced antioxidant defense, and downstream neuroendocrine dysfunction. Khavinson's research documented that Epithalamin (the complex extract) and to a lesser extent Epitalon treatment normalized the blunted evening melatonin surge in aged monkeys — one of the most relevant animal models for human aging given primate neurobiology. In elderly human patients at Khavinson's institute, Epithalamin treatment was associated with improved melatonin rhythms and sleep quality. This is the application the FDA is reviewing under PCAC July 24, 2026 — specifically insomnia. The sleep/melatonin indication is mechanistically coherent, has the most human-adjacent evidence (primate model, open-label human observation), and avoids the extraordinary claims that make the telomere application so contentious. Grade B-C: primate model + non-randomized human observation; Khavinson provenance; not RCT-validated.
Khavinson's group and collaborating oncologist Vladimir Anisimov documented lifespan extension in multiple rodent models with Epitalon and Epithalamin treatment. Key studies: Anisimov and Khavinson (2003) [4] — chronic Epitalon administration to aged female SHR rats extended mean lifespan by 13.3% compared to untreated controls, with reduced spontaneous tumor incidence. Anisimov and Khavinson (2002 [6], International Journal of Cancer) — Epitalon treatment reduced mammary tumor incidence and extended lifespan in HER-2/neu transgenic mice. Fruit fly (Drosophila melanogaster) experiments documented 16% lifespan extension. Grade C: consistent across multiple species and models; Anisimov's oncology expertise provides some independent credibility beyond pure Khavinson-internal work; lifespan extension in inbred laboratory rodents does not reliably predict longevity benefit in outbred heterogeneous human populations.
The claim that draws the most community attention: Epitalon activates telomerase and extends telomeres. The primary human-cell data: Khavinson et al. 2003 (human fetal lung fibroblasts, hTERT activation, Hayflick limit exceeded). The primary independent corroboration: Al-Dulaimi et al. 2025 (human cancer cell lines + fibroblasts, telomere elongation confirmed via both telomerase and ALT pathways). Grade C-D: replicated in cell culture with independent confirmation; mechanistically interesting; the critical gap is between cell culture telomere elongation and in vivo telomere maintenance in a living aging human. Whether SubQ injection of 5-10 mg Epitalon produces measurable telomere elongation in human blood leukocytes or target tissues — the outcome that would be clinically relevant — has never been tested in a controlled study.
THE IN VITRO TO IN VIVO GAP — SPECIFICALLY FOR TELOMERASE
Telomerase activation in cell culture is a different thing from telomere elongation in a living organism. In culture, Epitalon can be added at controlled concentrations directly to cells. In a living human, Epitalon is injected subcutaneously, distributed through the circulation at low concentrations, cleared by plasma peptidases with a short half-life, and must penetrate into cells in relevant tissues to activate hTERT. Whether the concentration of Epitalon achievable in human cells after SubQ injection is sufficient to produce the hTERT induction observed in direct cell culture exposure is not established. The community often treats the cell culture finding as proof of in vivo effect. It is proof of mechanism, not proof of clinical efficacy. These are different things.
The lifespan extension in tumor-prone mouse models is accompanied by reduced mammary tumor incidence — one of the more compelling findings because it has a specific measurable endpoint (tumor incidence) rather than a complex longevity endpoint. Anisimov is a legitimate oncological researcher with independent publications; his collaboration with Khavinson on the tumor work provides slightly better provenance than Khavinson-only publications. Grade C: replicated in two tumor models; Anisimov's involvement adds credibility; mechanism unclear; no human cancer prevention data.
A 2025 independent study (Gatta [9] et al., Stem Cell Reviews and Reports) documented that Epitalon enhances delayed wound healing in a diabetic retinopathy in vitro model. This is genuinely independent work (Italian researchers) unaffiliated with Khavinson, focused on retinal pigment epithelium wound healing. Grade D: 2025 in vitro; independent; new application area; preliminary.
A 2025 study documented Epitalon-activated telomerase enhancing bovine oocyte maturation rate and post-thawed embryo development. This is basic reproductive biology research, not a human longevity application, but it represents independent replication of the telomerase activation mechanism in a completely different biological context. Grade D: animal reproductive biology; independent; confirms telomerase activation in a non-Khavinson context.
Epitalon is a synthetic tetrapeptide: Alanine-Glutamic acid-Aspartic acid-Glycine (AEDG). Molecular formula C14H22N4O9. Molecular weight approximately 390 Da — among the smallest pharmacologically active peptides in this book, smaller even than ipamorelin (711 Da) or KPV (341 Da). The peptide is highly water-soluble due to its charged residues (glutamic acid, aspartic acid). It has no unusual structural features like D-amino acids (FOXO4-DRI), dimethylated residues (SS-31), or complex cyclization (PT-141) — it is four standard L-amino acids in sequence. This simplicity makes synthesis straightforward and relatively inexpensive. It also means proteolytic degradation is more rapid than structurally stabilized peptides — plasma half-life is short.
THIS DISTINCTION MATTERS FOR INTERPRETING EVERY PIECE OF EVIDENCE
Epithalamin and Epitalon are not interchangeable. Epithalamin is the original bovine pineal gland polypeptide extract — a complex mixture of biologically active peptide fractions from actual gland tissue. It is a registered pharmaceutical in Russia and was used in Khavinson's early clinical programs with elderly patients. Epitalon is the synthetic four-amino acid tetrapeptide (AEDG) derived from Epithalamin's active fraction. When reading any Epitalon paper or review, identify which compound was actually used. The 'human clinical data' most frequently cited — including the mortality reduction findings — was generated with Epithalamin, not pure synthetic Epitalon. Whether synthetic Epitalon produces identical effects to the complex Epithalamin extract is assumed but not systematically confirmed. The peptide community routinely conflates these compounds.
Compound
Type
Composition
Status
Used In
Epithalamin
Natural polypeptide extract
Complex mixture of bovine pineal peptide fractions
Registered medication in Russia
Early Khavinson clinical programs; the 'human clinical data'
Epitalon (Epithalon)
Synthetic tetrapeptide
AEDG (four amino acids)
Research chemical; PCAC July 2026
Most modern research; community use
Lyophilized Epitalon is stable at -20C for 18-24 months. Reconstituted with bacteriostatic water: refrigerate at 2-8C; use within 30 days. Solution is clear and colorless. The simple four-amino acid structure makes Epitalon relatively stable in solution compared to longer peptides, but peptidase degradation in plasma is rapid given the unmodified L-amino acid sequence. Mass spectrometry confirming ~390 Da is the identity check. HPLC purity 99%+ minimum. Pricing 2026: research vendor (HPLC + MS + endotoxin COA), 10 mg Epitalon: $20-40 — among the least expensive peptides in this book due to simple synthesis.
Community protocols use both SubQ injection and nasal spray. The published research — from Khavinson's group and in the Al-Dulaimi 2025 [2] cell line study — used injectable administration (subcutaneous or intraperitoneal in animal models). No pharmacokinetic comparison of nasal vs SubQ delivery has been published for Epitalon. The nasal route is community-driven convenience, not an evidence-supported route distinction. Given the short plasma half-life of an unmodified tetrapeptide, nasal bioavailability is likely lower and more variable than SubQ. Users preferring nasal spray should recognize they are choosing a less evidence-anchored route.
Epitalon's proposed mechanisms span telomere biology, pineal gland function, and gene regulation. The breadth of mechanistic claims is larger than the evidence for each individual mechanism. The telomere/telomerase mechanism is the most discussed and has the most direct published data, though primarily from one research group.
Telomeres are the repetitive DNA sequences (TTAGGG) at chromosome ends that protect chromosomes from degradation and end-to-end fusion. They shorten with each cell division. When telomeres reach a critical minimum length, the cell enters senescence or apoptosis — the Hayflick limit. Telomerase (hTERT, the catalytic subunit) is the enzyme that adds telomeric repeats to maintain telomere length. In most somatic cells, hTERT is transcriptionally silenced, meaning telomeres progressively shorten. Telomerase remains active in germ cells, stem cells, and — pathologically — most cancer cells.
Khavinson et al. (2003) reported that adding Epitalon to cultures of human fetal lung fibroblasts (cells that are telomerase-negative under normal conditions) activated hTERT expression and telomerase enzymatic activity. Treated cells demonstrated elongated telomeres and exceeded the Hayflick limit — dividing beyond the 50-70 division ceiling that normally marks the end of somatic cell proliferative capacity. If accurate and generalizable to living human tissue, this would represent one of the most significant findings in aging biology. Grade C-D: this is the Khavinson lab's own finding; the cell culture model is appropriate for mechanism demonstration; the specific result (telomerase activation in telomerase-negative somatic cells by a 4-amino acid peptide) remains mechanistically challenging to fully explain; independent replication was limited until 2025.
Al-Dulaimi et al. (Biogerontology, 2025): the first significant independent replication. Using human cancer cell lines (HeLa — telomerase-positive) and human fetal fibroblasts, this group from Brunel University London confirmed that Epitalon produced telomere elongation through both telomerase upregulation and alternative lengthening of telomeres (ALT activity). The mechanism may differ between telomerase-positive and telomerase-negative cell types. This is meaningful independent corroboration — but the cell types used (cancer cell lines and fetal fibroblasts) are different from the aged normal somatic cells that would be most relevant to the anti-aging application. Grade C: independent replication of telomere elongation; mechanism partially characterized; primary relevance to anti-aging in normal aged tissue not yet established.
The pineal gland's primary output — melatonin — declines progressively with age, contributing to circadian disruption, sleep deterioration, reduced antioxidant defense, and downstream neuroendocrine changes. Khavinson's group demonstrated in aged primate (monkey) models that Epitalon/Epithalamin treatment normalized the evening melatonin surge that characterizes younger individuals but is blunted in aging. In their human open-label program with elderly patients, Epithalamin treatment was associated with restored melatonin rhythms and improved sleep quality. The pineal stimulation mechanism is mechanistically plausible: Epitalon appears to act on pinealocytes (the melatonin-producing cells of the pineal gland) to enhance melatonin synthesis. This is the application the FDA is reviewing for PCAC July 24, 2026 — insomnia. It is also the most defensible and mechanistically coherent application for Epitalon given the evidence. Grade B-C: primate model + human open-label (Khavinson); mechanism coherent; not RCT-validated.
More recent work from Khavinson's group (2020 [8], Molecules) documented that Epitalon binds to methylated cytosine in DNA and to the linker histone protein H1 (specifically H1.3 and H1.6), suggesting a direct epigenetic regulatory role. H1 binding could influence chromatin compaction and gene expression programs relevant to aging. This mechanistic finding provides a potential explanation for how a four-amino acid peptide could influence hTERT expression — through direct chromatin interactions that alter the accessibility of the telomerase gene promoter. Grade D: in vitro mechanistic study; Khavinson group; not independently replicated; potentially important for explaining the telomerase claim but not validated.
Animal studies from the Khavinson group document that Epitalon increases superoxide dismutase (SOD) and glutathione peroxidase activity in aged tissue — a pattern consistent with enhanced antioxidant defense. These antioxidant effects are coherent with the pineal/melatonin mechanism (melatonin itself is a potent antioxidant) and could explain some of the anti-tumor effects observed in animal models. Grade C: animal data; Khavinson group; antioxidant mechanism coherent with other documented effects.
MECHANISM REALITY CHECK
Epitalon has four proposed mechanisms: telomerase activation, pineal stimulation, epigenetic DNA/histone binding, and antioxidant effects. Of these, the pineal/melatonin mechanism has the most mechanistically coherent evidence and the most human-relevant (if not RCT-quality) data. The telomerase mechanism is the most exciting and the least independently verified. The epigenetic mechanism is the most speculative but could theoretically unify the other three. All of these come overwhelmingly from Khavinson's group. The Al-Dulaimi 2025 paper is the first meaningful crack of daylight from an independent Western laboratory — and it confirms telomere elongation while adding mechanistic complexity (ALT pathway). This is progress, but it is not replication of the full claim in the population that matters most for the community use case: normal aging human cells.
Khavinson's group has documented Epitalon-related gene expression changes across multiple publications. The most relevant: upregulation of hTERT (telomerase catalytic subunit) gene expression in treated fibroblasts; upregulation of antioxidant genes (SOD, glutathione peroxidase); modulation of genes involved in neurogenesis (documented in a 2020 Molecules paper studying Epitalon's effects on neuronal gene expression); and putative epigenetic effects via H1 histone and methylated DNA binding. The scope of claimed gene expression effects is broad for a four-amino acid peptide. The Al-Dulaimi 2025 paper added an independent perspective: upregulation of both TERT (telomerase pathway) and ALT-related pathways in cancer cell lines. The gene expression picture from Khavinson's group is internally consistent and spans decades; the independently confirmed piece is limited to the telomere-maintenance genetic machinery. No transcriptomic study of Epitalon effects in normal aged human cells has been published.
THE 'HUMAN CLINICAL DATA' FRAMING — A NECESSARY CLARIFICATION
Epitalon is frequently described as having 'decades of human clinical data.' This is technically accurate but requires careful unpacking. The human data consists of: (1) open-label non-randomized observations of elderly patients treated at Khavinson's own institute, compared to historical controls — not randomized controlled trials; (2) much of this data was generated with Epithalamin (the complex extract), not pure synthetic Epitalon; (3) a 6-year follow-up showing 1.6-1.8x mortality reduction and a 15-year follow-up showing 2.5x reduction in combined pineal + thymus peptide treatment — these are non-randomized, single-institution, historically-controlled observations from the institution that developed and has commercial interest in the compound. There is no RCT. There is no placebo-controlled trial. The human data is real. Its evidence grade is not what the marketing implies.
Claim
Model
Evidence Type
Grade
Limitation
Telomerase activation in somatic cells
Human fetal fibroblasts (in vitro)
Cell culture, Khavinson 2003
C-D
Khavinson provenance; cell culture ≠ in vivo; not replicated independently until 2025
Telomere elongation in human cell lines
HeLa + fibroblasts (in vitro)
Cell culture, Al-Dulaimi 2025 INDEPENDENT
C
Cancer cell lines differ from normal aged tissue; still cell culture
Lifespan extension 12-13%
Aged female SHR rats
Animal, Khavinson + Anisimov
C
Inbred strain; Khavinson provenance dominant; species translation uncertain
Lifespan extension 16%
Drosophila melanogaster
Animal, Khavinson
C
Fly lifespan ≠ mammalian aging; Khavinson only
Reduced mammary tumor incidence
HER-2/neu transgenic mice
Animal, Anisimov + Khavinson
C
Transgenic tumor model; Anisimov adds credibility; no human cancer data
Melatonin restoration
Aged monkeys
Primate animal model, Khavinson
B-C
Non-human primate; Khavinson; compelling for insomnia claim
Melatonin/sleep improvement (humans)
Elderly patients, open-label
Non-RCT, Khavinson institute
B-C
Non-randomized; single institution; Epithalamin not pure Epitalon
1.6-1.8x mortality reduction
Elderly patients, 6-year observation
Historical comparator design
C-D
Not randomized; historical controls; Epithalamin; Khavinson institute
Telomere elongation in living humans
None
None
X
Not demonstrated in any controlled human study
DOSING CONTEXT
Epitalon has no FDA-approved dose for any indication. No human pharmacokinetic study has been published for Epitalon specifically. Community protocols are derived from Khavinson's animal study doses (scaled) and from the open-label human programs using Epithalamin — not pure synthetic Epitalon. The FDA is reviewing Epitalon for insomnia (PCAC July 24, 2026), not for anti-aging or telomere lengthening. All community anti-aging protocols are off-label extrapolations from an already non-approved compound.
Adjust any input. The syringe draw updates live. Tap a preset row to load that dilution.
| BAC | Concentration | Per unit | Notes |
|---|---|---|---|
| 1 mL | 10,000 mcg/mL | 1 mcg | Standard — single dose if using 10mg protocol |
| 2 mL | 5,000 mcg/mL | 2 mcg | Lower concentration; more precise dosing at lower doses |
| 1 mL | 5,000 mcg/mL | 1 mcg | Smaller vial; 5mg dose |
Epitalon's plasma half-life is short — estimated at 30-90 minutes for an unmodified L-amino acid tetrapeptide without structural stabilization (unlike D-retro-inverso FOXO4-DRI or the pyroglutamate-stabilized ARA-290). Rapid peptidase degradation in plasma limits systemic exposure duration. This short half-life is one reason community protocols favor daily dosing during cycles rather than weekly or biweekly dosing. No published pharmacokinetic study exists for human Epitalon administration. Subcutaneous injection produces systemic distribution; the peptide's small size (~390 Da) allows reasonably efficient tissue distribution. Whether intracellular concentrations sufficient for hTERT induction are achieved in relevant aging tissues after SubQ injection has not been measured.
Epitalon: lyophilized powder reconstituted with bacteriostatic water. Simple synthesis and high water solubility make reconstitution straightforward. Solution is clear and colorless. Refrigerate at 2-8C after reconstitution; use within 30 days. Mass spectrometry confirming ~390 Da. HPLC purity 99%+ minimum. At ~$25-40 per 10 mg vial from reputable vendors, Epitalon is one of the least expensive compounds in this book, which reduces the financial barrier to community use but also reduces the economic incentive for vendors to invest in comprehensive quality testing. COA with batch-specific endotoxin testing remains important.
Vial Size
BAC Water
Concentration
Volume for 10 mg
Notes
10 mg
1.0 mL
10,000 mcg/mL
1.0 mL (100 units)
Standard — single dose if using 10mg protocol
10 mg
2.0 mL
5,000 mcg/mL
2.0 mL (200 units)
Lower concentration; more precise dosing at lower doses
5 mg
1.0 mL
5,000 mcg/mL
1.0 mL (100 units)
Smaller vial; 5mg dose
Protocol
Dose
Frequency
Duration
Cycles per Year
Conservative
5 mg
Daily SubQ
10 days
2-3
Standard community
10 mg
Daily SubQ
10-20 days
2-3
Extended course
5-10 mg
Daily SubQ
20 days
2
Nasal spray (community)
1-2 mg per nostril
Daily
10-20 days
2-3 (less evidence than SubQ)
The cyclic rather than continuous protocol is standard in Khavinson's work and makes biological sense for a compound that appears to reset or restore regulatory signals rather than continuously supplementing them. The 10-20 day course mirrors the protocols used in Khavinson's observational programs with Epithalamin. Longer continuous use has not been documented to produce proportionally greater benefit and may produce tolerance or receptor adaptation — this is speculative, not documented.
No specific circadian timing requirement established for the longevity or telomere applications. For the insomnia/melatonin application, evening administration before sleep is most consistent with the proposed mechanism (stimulating the evening melatonin surge). Community users interested in the sleep application typically administer in the evening; those focused on longevity applications vary — morning or evening both reported.
No standard monitoring requirement. The most directly relevant biomarker for the telomere hypothesis — telomere length — can be measured via commercial testing (TeloYears, Life Length, and similar services offer leukocyte telomere length measurement). If a user wants objective evidence for whether Epitalon is affecting their telomere length, this is the measurement, with the caveat that leukocyte telomere length measurement has significant variability and the biological significance of measured telomere length changes in blood cells (as opposed to relevant aging tissues) is itself debated. For the sleep application: subjective sleep quality metrics and morning cortisol/melatonin saliva testing.
Across Khavinson's published programs and the limited independent studies, Epitalon has a consistently clean safety profile. No serious adverse events attributable to Epitalon have been reported. No organ toxicity, no significant endocrine disruption, no cardiovascular signals. The simple four-amino acid structure provides some reassurance — there are fewer complex functional groups to produce off-target receptor binding compared to the structurally complex compounds in this book. The short plasma half-life limits exposure duration. Published data suggests the safety profile is genuinely favorable.
The telomere and telomerase mechanism creates a theoretical concern that is rarely discussed in community discourse: telomerase activation in somatic cells is the same pathway that drives cancer cell immortality. Telomerase reactivation in normal aged cells is the proposed therapeutic benefit — but if Epitalon were to activate telomerase in pre-cancerous cells with partial p53 dysfunction, it could theoretically contribute to malignant transformation rather than healthy longevity. This concern is different from FOXO4-DRI's p53 mechanism (which is much more directly consequential) — the telomerase concern is more speculative, and cancer biology research generally shows that telomerase activation alone is insufficient for malignant transformation. However, the theoretical concern exists and is not acknowledged in most Epitalon marketing.
WADA STATUS — NOT CURRENTLY BANNED
Epitalon is not listed on the 2026 WADA Prohibited List in any category. No S0-S5 section covers pineal peptides or telomerase activators. Athletes can currently use Epitalon without a known WADA violation. Unlike MOTS-c (S4 explicit named ban) or ARA-290 (S2 EPO-related), Epitalon has no WADA coverage issue. This is one of the cleaner WADA statuses in the longevity section of this book. Verify current status before competition use as lists evolve annually.
Epitalon's proposed mechanism — telomerase activation and pineal gland restoration — is distinct from every other compound in this book. It does not compete with mitochondrial compounds (SS-31, MOTS-c), healing peptides (BPC-157, TB-500, GHK-Cu), GH secretagogues (CJC/Ipa), or senolytics (FOXO4-DRI). Its natural combination partners are other longevity-focused compounds.
The mechanistic argument: FOXO4-DRI clears accumulated senescent cells (cells with critically short telomeres and dysfunctional SASP production); Epitalon may help maintain telomere length in the surviving normal cells, potentially slowing the rate at which those cells accumulate future senescence. The combination addresses two complementary aspects of cellular aging — clearing existing senescent burden (FOXO4-DRI) and potentially maintaining telomere integrity in healthy cells (Epitalon). The clear-then-maintain logic is mechanistically coherent. No data. FOXO4-DRI is an absolute contraindication for anyone with active malignancy; Epitalon's theoretical telomerase concern applies to the same population.
MOTS-c addresses metabolic/mitochondrial function; Epitalon addresses telomere maintenance and pineal function. Non-overlapping mechanisms, genuinely complementary longevity axes. Both are on the PCAC schedule (MOTS-c July 23; Epitalon July 24). No pharmacological conflicts. No interaction data.
SS-31 addresses the structural integrity of the inner mitochondrial membrane (cardiolipin stabilization). Epitalon addresses telomere maintenance and pineal regulation. The combination would target two distinct biological dimensions of cellular aging — energy production infrastructure and chromosomal stability. Community longevity stacks often include both. No interaction data.
If Epitalon's primary mechanism for sleep is stimulating endogenous melatonin production, combining it with direct melatonin supplementation creates potential redundancy and could theoretically suppress the pineal stimulation signal (exogenous melatonin might feedback to reduce pineal synthesis). Whether this interaction is clinically meaningful at standard doses is unknown. Users taking melatonin for sleep who want to add Epitalon might consider timing separation or rotating rather than simultaneous use.
Sleep/melatonin
General longevity users
Sleep/melatonin
Telomere/longevity
Epitalon's timeline of effects differs depending on which application is being considered. For the sleep/melatonin application (the most evidence-anchored): effects on sleep quality and circadian rhythm are reported within the first few days of a course — consistent with the rapid hormonal effects of pineal stimulation. For the longevity/telomere application: no meaningful timeline exists because no controlled trial has documented the effect in humans. The community-reported timeline below is Grade E throughout.
Timeframe
Application
What's Reported (Grade E for longevity claims)
Days 1-5
Sleep/melatonin
Improved sleep depth and morning feeling within first cycle days in many users. Evening dosing reports best results. This is the most consistently reported early effect.
Week 1-2
General longevity users
Improved sleep quality persisting (consistent with mechanism). Some users report improved mood and energy — possibly sleep-quality downstream. No objective longevity markers expected at this stage.
Post-course (weeks-months)
Sleep/melatonin
Sleep improvements persist for some users after cycle ends — consistent with pineal function restoration rather than pharmacological substitution.
Long-term (months-years)
Telomere/longevity
No documented timeline. Community users who test telomere length periodically and attribute changes to Epitalon are reporting uncontrolled single observations that cannot be distinguished from normal telomere length variability. This is not clinical evidence.
For community users specifically interested in Epitalon's sleep-improving effects — which have the most plausible mechanism and the most human-adjacent evidence — evening dosing protocol is most relevant. 5-10 mg SubQ or nasal spray in the evening, 10-20 consecutive days, 2-3 times per year. This matches the PCAC insomnia indication framing. Users with age-related sleep deterioration, circadian disruption, or evening melatonin rhythm blunting represent the most appropriate community population for this application.
Cyclic protocols (10-20 days on, 2-3 months off) are standard in Khavinson's program and represent the best-documented use pattern. The biological rationale: Epitalon appears to restore or reset regulatory signals (pineal function, epigenetic state) rather than continuously supplement a deficient molecule. A pulsed protocol that periodically resets the system may be more physiologically appropriate than continuous supplementation. No comparative data on cyclic vs continuous use exists.
Epitalon is among the least expensive research peptides available — simple four-amino acid synthesis from commodity L-amino acids, high water solubility, no structural modifications. Pricing 2026: research vendor (HPLC + MS + endotoxin COA), 10 mg Epitalon: $20-40. The low cost creates a large and competitive vendor market but reduces the economic incentive for rigorous quality testing. COA with batch-specific HPLC purity (99%+), mass spectrometry at ~390 Da, and endotoxin testing remains important. At this price point, the incremental cost of a quality-verified vendor over the cheapest available product is small and well-justified.
Epitalon has the longest community use history of any compound in the longevity section of this book — it entered the biohacking community years before MOTS-c, FOXO4-DRI, or SS-31. Its users span from serious longevity researchers to general biohackers to people with specific sleep concerns. The community consensus is more fragmented than for compounds with cleaner evidence — some users report meaningful sleep quality improvements (consistent with mechanism); others report subtle energy and cognitive effects; others report nothing perceptible. The telomere-focused community tends toward long-term use with periodic commercial telomere testing as the objective measurement, though individual telomere test results are highly variable and cannot substitute for controlled trial data.
Epitalon has the widest gap between research breadth and research independence of any compound in this book. The questions are not 'we know nothing' — 40 years of consistent data answer some things. The questions are 'can we trust what we know from a single source, and does any of it translate to the application the community cares about most?'
The honest position on Epitalon in 2026: the compound with the longest research history and the most concentrated provenance of any longevity compound in this book. Forty years of internally consistent research from one institute. The telomerase activation finding — the thing the community most cares about — was published in 2003 and received its first meaningful independent corroboration in 2025. The sleep/melatonin application is the most defensible and is the FDA's focus for PCAC review. The community's primary interest is in the telomere application, for which the human evidence is the weakest. Whether Epitalon deserves the confidence the longevity community places in it depends entirely on whether 'consistent data from one source' is a sufficient substitute for 'independently replicated data from multiple sources.' The answer to that question is the central scientific problem with the entire Epitalon evidence base.
Research provenance — a frank statement: the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology has dominated Epitalon research for 40 years. Independent replication was extremely limited before 2025. When reading any Epitalon paper, check the author list and affiliation before assessing evidential weight. Recent independent publications (Al-Dulaimi 2025, Gatta 2025, bovine oocyte 2025) represent meaningful progress toward external validation.
Khavinson VK, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 135(6):590-592. [THE primary telomerase paper — hTERT activation, Hayflick limit exceeded in human fetal fibroblasts; Khavinson institute; cited in virtually all subsequent Epitalon literature]
Al-Dulaimi S, Matta S, Slijepcevic P, Roberts T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 26(5):178. PMC12411320. [INDEPENDENT — Brunel University London; first significant Western replication; confirmed telomere elongation via both telomerase and ALT pathways in HeLa and fibroblasts; 22 years after Khavinson 2003]
Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. (2025) [3]. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 26(6):2691. PMC11943447. [2025 comprehensive review; international authors; useful for full literature survey; acknowledges provenance concentration]
Anisimov VN, Khavinson VK, et al. (2003). Epithalon decapeptide and its synthetic tetrapeptide analog epitalon retard aging and increase lifespan of Drosophila melanogaster. Mechanisms of Ageing and Development. 124(9):1-6. [Drosophila 16% lifespan extension; Khavinson + Anisimov collaboration]
Anisimov VN, Khavinson VK. (2010) [5]. Peptide bioregulation of aging: results and prospects. Biogerontology. 11(2):139-49. PMID: 19291403. [Comprehensive review of Khavinson bioregulator program including lifespan data across species; Anisimov is an independent oncologist whose collaboration adds credibility]
Anisimov VN, Khavinson VK, et al. (2002). Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 101(1):7-10. [Tumor incidence reduction + lifespan extension; oncology journal; Anisimov primary]
Khavinson VK, et al. (2001) [7]. Epithalamin increases the lifespan of fruit flies, mice and rats. Bulletin of Experimental Biology and Medicine. [Melatonin restoration in aged models; circadian rhythm normalization]
Khavinson V, Diomede F, Mironova E, et al. (2020). AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 25(3):609. doi:10.3390/molecules25030609. [H1 histone binding mechanism; gene expression modulation; Khavinson group]
Gatta M, Dovizio M, Milillo C, et al. (2025). The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem Cell Reviews and Reports. 21:1822-1834. [INDEPENDENT — Italian researchers; retinal wound healing; new application; independent of Khavinson]
Life Sciences. (2025) [10]. Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. 362:123381. [INDEPENDENT — reproductive biology; telomerase activation confirmed in completely different biological context; non-Khavinson]
FDA Advisory Committee Calendar. (2026). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Epitalon (free base and acetate) reviewed for insomnia indication, July 24, 2026 (Day 2). Docket: FDA-2025-N-6895.
FDA. (2026, April 22). Epitalon removed from 503A Category 2 bulk drug substances list. PCAC review July 24, 2026 alongside Emideltide (DSIP) and Semax.
Epitalon is the compound in this book where the research history is longest, the provenance problem is most acute, and the gap between what the community believes and what the evidence actually shows is widest. Forty years of research is remarkable. The fact that nearly all of it comes from one scientist and one institution is the defining caveat.
The central tension resolved: Vladimir Khavinson discovered Epitalon, synthesized Epitalon, studied Epitalon, published on Epitalon, continues to publish on Epitalon, and leads the institution that holds commercial interest in Epitalon-related compounds. This is not a disqualification — every compound starts with a developer. But it is a limitation that compound science is designed to address through independent replication. Selank's Russian approval, reviewed in this book, came from two independent Russian institutions. Semax has Dolotov 2006 — an independent researcher confirming the BDNF finding. Epitalon's central claim — the one the entire longevity community is excited about — went 22 years without a meaningful independent attempt at replication. The Al-Dulaimi 2025 paper is a positive development. One paper from one independent group, 22 years later, confirming telomere elongation in cancer cell lines, is not the same as an established evidence base.
The strongest argument for Epitalon: it is the most mechanistically interesting longevity compound in this book from a pure biology perspective. Telomerase activation by a four-amino acid peptide, if the mechanism is real and generalizable, represents a genuinely elegant biological insight. The pineal/melatonin mechanism is well-supported and has a clear human application (sleep quality in aging). The animal data is consistent across species. The safety profile is genuinely clean. The compound has been studied for longer than any other in this book. And the 2025 wave of independent publications (Al-Dulaimi, Gatta, bovine oocyte) suggests the field is finally receiving the independent attention it has long deserved.
The strongest argument for caution: the evidence architecture is structurally fragile. One motivated researcher, one institution, 40 years of internally consistent data, one independent replication. The human 'clinical data' is non-randomized, single-institution, uses a different compound (Epithalamin), and was generated by the same people who developed and commercialize the compound. The most exciting claim — telomere elongation in living humans — has never been tested in a controlled trial. The PCAC review is for insomnia, not longevity, reflecting the FDA's appropriately conservative reading of what the evidence actually supports.
Epitalon is the compound in this book where the research history is longest, the provenance problem is most acute, and the gap between what the community believes and what the evidence actually shows is widest. Forty years of research is remarkable. The fact that nearly all of it comes from one scientist and one institution is the defining caveat.
The central tension resolved: Vladimir Khavinson discovered Epitalon, synthesized Epitalon, studied Epitalon, published on Epitalon, continues to publish on Epitalon, and leads the institution that holds commercial interest in Epitalon-related compounds. This is not a disqualification — every compound starts with a developer. But it is a limitation that compound science is designed to address through independent replication. Selank's Russian approval, reviewed in this book, came from two independent Russian institutions. Semax has Dolotov 2006 — an independent researcher confirming the BDNF finding. Epitalon's central claim — the one the entire longevity community is excited about — went 22 years without a meaningful independent attempt at replication. The Al-Dulaimi 2025 paper is a positive development. One paper from one independent group, 22 years later, confirming telomere elongation in cancer cell lines, is not the same as an established evidence base.
The strongest argument for Epitalon: it is the most mechanistically interesting longevity compound in this book from a pure biology perspective. Telomerase activation by a four-amino acid peptide, if the mechanism is real and generalizable, represents a genuinely elegant biological insight. The pineal/melatonin mechanism is well-supported and has a clear human application (sleep quality in aging). The animal data is consistent across species. The safety profile is genuinely clean. The compound has been studied for longer than any other in this book. And the 2025 wave of independent publications (Al-Dulaimi, Gatta, bovine oocyte) suggests the field is finally receiving the independent attention it has long deserved.
The strongest argument for caution: the evidence architecture is structurally fragile. One motivated researcher, one institution, 40 years of internally consistent data, one independent replication. The human 'clinical data' is non-randomized, single-institution, uses a different compound (Epithalamin), and was generated by the same people who developed and commercialize the compound. The most exciting claim — telomere elongation in living humans — has never been tested in a controlled trial. The PCAC review is for insomnia, not longevity, reflecting the FDA's appropriately conservative reading of what the evidence actually supports.
Well-suited for: adults over 50 with age-related sleep deterioration or disrupted circadian rhythm, for whom the melatonin-restorative mechanism provides the most evidence-anchored rationale; longevity-focused biohackers who understand the provenance limitations and are willing to self-experiment with a compound that has a plausible mechanism and clean safety profile; users interested in the broader Khavinson bioregulator paradigm who want to start with the most-studied compound in that class.
Extra caution for: anyone with active malignancy or strong cancer family history (theoretical telomerase concern in pre-cancerous cells); users who intend to cite the Epitalon evidence base as 'decades of proven human clinical data' — that framing misrepresents the actual evidence quality; anyone making major health decisions based primarily on Epitalon's marketing claims rather than its actual evidence.
Not appropriate for: anyone expecting rapid perceptible longevity effects; anyone treating the 40-year Khavinson research history as equivalent to 40 years of independent replicated science; anyone combining with Epithalamin under the assumption they are the same compound with equivalent bioavailability and potency.
Epitalon is the most-studied compound from a broader research program that Khavinson has developed over 50 years. The Khavinson bioregulators are short peptides (2-4 amino acids) derived from specific organ extracts, each purported to restore the regulatory function of the source organ. Pinealon (Ala-Glu-Asp-Arg, derived from brain cortex) is studied for neuroprotection. Prostamax (Ala-Glu-Asp-Gln, from prostate) for prostate function. Thymulin analogs for immune function. The framework is internally coherent: organ-specific signaling peptides that restore age-related decline in target tissue function. Whether the framework is correct depends on replication from sources other than Khavinson's group — the same core question that defines Epitalon's evidence status. Epitalon is the best-studied and best-evidenced member of this class. That says something positive about Epitalon. It also places every other Khavinson bioregulator at an even greater evidentiary discount.
— End of Epitalon —
THE PEPTIDE BIBLE | Epitalon | For Research & Educational Purposes Only
Epitalon (Epithalon, Epithalone) is a synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), molecular weight ~390 Da. Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s as a synthetic version of Epithalamin — a bovine pineal gland polypeptide extract. Critical distinction: Epithalamin (complex extract, registered pharmaceutical in Russia) ≠ Epitalon (pure synthetic tetrapeptide). Most 'human clinical data' was generated with Epithalamin. Primary proposed mechanisms: telomerase (hTERT) activation in somatic cells; pineal gland stimulation → melatonin restoration; antioxidant enzyme upregulation; epigenetic regulation via DNA/histone H1 binding. Key telomerase finding: Khavinson et al. 2003 — hTERT activation and Hayflick limit exceeded in human fetal lung fibroblasts; Grade C-D given Khavinson provenance and 22-year wait for independent replication. First significant independent replication: Al-Dulaimi et al. (Biogerontology, 2025) — telomere elongation confirmed in human cell lines via telomerase + ALT pathways; Grade C (cancer cell lines; independent; meaningful progress). Animal lifespan extension: 12-24% in rodents (Khavinson + Anisimov); 16% in Drosophila; Grade C. Human data: non-randomized open-label observations at Khavinson's institute; 1.6-1.8x mortality reduction with Epithalamin over 6-year follow-up; not RCT; Grade C-D. PCAC regulatory situation: FDA reviewing Epitalon July 24, 2026 for insomnia indication (the melatonin/sleep application) — the most defensible and best-evidenced application. Community dosing: 5-10 mg/day SubQ (or nasal), 10-20 days per cycle, 2-3 cycles per year. Safety: clean profile; no serious adverse events documented; mild injection site reactions; theoretical telomerase/cancer concern applies to pre-cancerous cell populations. WADA: not listed on 2026 Prohibited List. The central tension: 40 years of research from one institution that developed, patented, and commercializes the compound. The first independent Western replication of the headline telomerase claim appeared in 2025. Whether Epitalon extends telomeres in living aging humans — the community's primary interest — has never been tested in a controlled trial.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.